Cara Therapeutics, Inc. (CARA)

NASDAQ: CARA · IEX Real-Time Price · USD
1.68
-0.01 (-0.59%)
At close: Sep 29, 2023, 4:00 PM
1.71
+0.03 (1.79%)
After-hours: Sep 29, 2023, 7:55 PM EDT
-0.59%
Market Cap 90.85M
Revenue (ttm) 27.17M
Net Income (ttm) -111.66M
Shares Out 54.08M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 419,306
Open 1.69
Previous Close 1.69
Day's Range 1.67 - 1.74
52-Week Range 1.59 - 12.81
Beta 0.87
Analysts Strong Buy
Price Target 17.50 (+941.67%)
Earnings Date Nov 6, 2023

About CARA

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 106
Stock Exchange NASDAQ
Ticker Symbol CARA
Full Company Profile

Financial Performance

In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CARA stock is "Strong Buy." The 12-month stock price forecast is $17.5, which is an increase of 941.67% from the latest price.

Price Target
$17.5
(941.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients

STAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

6 days ago - GlobeNewsWire

Cara Therapeutics Reports Second Quarter 2023 Financial Results

– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

7 weeks ago - GlobeNewsWire

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

2 months ago - GlobeNewsWire

Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

2 months ago - GlobeNewsWire

Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023

STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

2 months ago - GlobeNewsWire

Cara Therapeutics to Present at the Jefferies Healthcare Conference

STAMFORD, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

4 months ago - GlobeNewsWire

Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in ad...

4 months ago - PRNewsWire

Cara Therapeutics Reports First Quarter 2023 Financial Results

– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company's share of profit of KORSUVA ® (difelikefalin) injection –

4 months ago - GlobeNewsWire

Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,

5 months ago - MarijuanaStocks

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients...

5 months ago - GlobeNewsWire

Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 10, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

6 months ago - GlobeNewsWire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AHCOINFIOPRXTKNO
7 months ago - Benzinga

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

7 months ago - GlobeNewsWire

Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss

Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.

7 months ago - Yahoo Finance

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company's share of profit of KORSUVA ® (difelikefalin) injection; FY22 revenue was $41.9 million includin...

7 months ago - GlobeNewsWire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

7 months ago - GlobeNewsWire

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment Publication underscores the importance of data in underrecognized neuropat...

8 months ago - GlobeNewsWire

Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

9 months ago - GlobeNewsWire

Cara Therapeutics Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

9 months ago - GlobeNewsWire

Cara Therapeutics Reports Third Quarter 2022 Financial Results

– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA ® (difelikefalin) injection –

11 months ago - GlobeNewsWire

Cara Therapeutics to Present at Upcoming Investor Conferences

STAMFORD, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

11 months ago - GlobeNewsWire

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patient...

1 year ago - GlobeNewsWire

SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

Milestone payment highlights ongoing clinical progress of Oral KORSUVA™ DALLAS , Oct. 10 2022  /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance compan...

Other symbols: SWKH
1 year ago - PRNewsWire

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

1 year ago - GlobeNewsWire

Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien...

1 year ago - GlobeNewsWire